Edgewise Therapeutics, Inc. financial data

Symbol
EWTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1715 38 Th St, Boulder, CO
State of incorporation
Delaware
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.6K % +7.51%
Debt-to-equity 4.97 % -8.14%
Return On Equity -28 % -16.3%
Return On Assets -26.7 % -16.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 93.8M shares +47.8%
Common Stock, Shares, Outstanding 93.6M shares +47.6%
Entity Public Float 386M USD +55.7%
Common Stock, Value, Issued 9K USD +50%
Weighted Average Number of Shares Outstanding, Basic 93.5M shares +47.5%
Weighted Average Number of Shares Outstanding, Diluted 93.5M shares +47.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 110M USD +57.1%
General and Administrative Expense 26.3M USD +22.8%
Operating Income (Loss) -136M USD -49%
Net Income (Loss) Attributable to Parent -116M USD -42.7%
Earnings Per Share, Basic -1.54 USD/shares -14.9%
Earnings Per Share, Diluted -1.54 USD/shares -14.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 43.5M USD +36.7%
Assets, Current 519M USD +63.9%
Property, Plant and Equipment, Net 9.9M USD -8.83%
Operating Lease, Right-of-Use Asset 2.05M USD -13%
Other Assets, Noncurrent 262K USD -37.5%
Assets 532M USD +60.8%
Accounts Payable, Current 6.8M USD +79.9%
Employee-related Liabilities, Current 4.24M USD +35.8%
Accrued Liabilities, Current 5.14M USD -22.3%
Liabilities, Current 17.2M USD +19.3%
Operating Lease, Liability, Noncurrent 4M USD -16.2%
Other Liabilities, Noncurrent 192K USD
Liabilities 21.2M USD +10.4%
Accumulated Other Comprehensive Income (Loss), Net of Tax -1.05M USD -92.7%
Retained Earnings (Accumulated Deficit) -305M USD -61.3%
Stockholders' Equity Attributable to Parent 510M USD +63.9%
Liabilities and Equity 532M USD +60.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -28.6M USD -25.3%
Net Cash Provided by (Used in) Financing Activities 241M USD
Net Cash Provided by (Used in) Investing Activities -268M USD -647%
Common Stock, Shares Authorized 1B shares 0%
Common Stock, Shares, Issued 93.6M shares +47.6%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -55.8M USD -313%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 43.5M USD +36.7%
Deferred Tax Assets, Valuation Allowance 69.6M USD +74.2%
Deferred Tax Assets, Gross 69.6M USD +74.2%
Operating Lease, Liability 2.2M USD
Depreciation 1.93M USD +147%
Payments to Acquire Property, Plant, and Equipment 297K USD -93.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -116M USD -46.5%
Lessee, Operating Lease, Liability, to be Paid 3.3M USD
Property, Plant and Equipment, Gross 13.5M USD +7.38%
Operating Lease, Liability, Current 988K USD +13.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 328K USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 777K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 446K USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 200M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 457K USD
Additional Paid in Capital 816M USD +63%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 19.8M USD +34.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%